The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
 
Manisha H. Shah
Consulting or Advisory Role - Eisai; Loxo
Research Funding - Bristol-Myers Squibb; Eisai; Merck
 
Lai Wei
No Relationships to Disclose
 
Lori J. Wirth
Consulting or Advisory Role - Amgen; Blueprint Medicines; Eisai; Loxo; Merck
Research Funding - AstraZeneca; Bayer; Eisai
 
Gregory A. Daniels
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Prometheus (Inst); Viralytics (Inst)
 
Jonas A. De Souza
No Relationships to Disclose
 
Cynthia Dawn Timmers
Stock and Other Ownership Interests - Array BioPharma; Seagen
 
Jennifer L. Sexton
No Relationships to Disclose
 
Mamdouh Beshara
No Relationships to Disclose
 
Debra Nichols
No Relationships to Disclose
 
Norka Snyder
No Relationships to Disclose
 
Catherine E Devine
No Relationships to Disclose
 
Bhavana Konda
No Relationships to Disclose
 
Naifa Lamki Busaidy
Consulting or Advisory Role - Bayer; Eisai